remynd Email Format

Biotechnology ResearchFlanders, Belgium11-50 Employees

Remynd is a clinical-stage biotechnology company focused on developing first-in-class oral therapies for neurodegenerative diseases, notably Alzheimer’s disease and Huntington’s disease. By targeting the fundamental mechanisms of these conditions, the company aims to restore neuronal function and slow progression. Based in Heverlee, in the Flanders region of Belgium, Remynd operates as a small to mid-sized team within the biotechnology research sector and advances its drug candidates from discovery toward clinical development.

In December 2020, Remynd announced leadership changes as part of its transition into a clinical-stage company, appointing a Chief Medical Officer and a new Board Chair. This move reflects its progression toward advancing therapies into clinical development with a focus on patient impact.

Sign up for free to view info

Company overview Employee directory